Opus Genetics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -12.2%
EBITDA: —
EBIT: +33.1%
EPS: +32.5%
Free cash flow: -35.1%
Operating cash flow: -35.1%

Forward estimates

Revenue: +53.0%
EBITDA: +96.3%
EPS: +73.4%

Three-year CAGR

Revenue: -29.1%
EBITDA: +16.4%
EBIT: +37.8%
Net income: +13.8%
EPS: +62.8%
Free cash flow: -37.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.